IP Library › Granted Patent US 12,282,022
Granted Patent B2
US 12,282,022 · App. 16/469,082 · Granted Apr 22, 2025

Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples for detection and treatment monitoring

Inventors: Ye Hu (Scottsdale, AZ); Jia Fan (Pearland, TX); Kai Liang (Beijing, CN); Fei Liu (Cupertino, CA); Dali Sun (Tempe, AZ)
Assignee: THE METHODIST HOSPITAL
G01N33/57438G01N33/54346
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,282,022
App. No.
16/469,082
Granted
Apr 22, 2025
Kind
B2
Abstract

A rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumor-derived EVs from as little as 1 μ{umlaut over ({acute over (ι)})}, of plasma is described herein. This assay uses binding of gold nanospheres and nanorods with EV- and tumor-derived EV-specificities to produce a local plasmon effect that enhances tumor-derived EV detection sensitivity and specificity. This nPES approach is also a non-invasive method for assessing pancreatic cancer stage and treatment response that can be easily refined for clinical use, and is readily adapted for diagnosis and monitoring of other conditions with disease-specific EV proteins.

Claims (13)

1. A method of detecting a cancer specific protein that is enriched on an extracellular vesicle (EV), comprising:

contacting a sample comprising the EV with a surface conjugated with a first antibody directed to a first molecule on the EV to capture the EV on the surface;

removing the remainder of the sample from the surface to generate separated EV captured on the surface;

incubating the separated EV captured on the surface with a first set of nanoparticles conjugated with a second antibody directed to the cancer specific protein on the EV and incubating the separated EV captured on the surface with a second set of nanoparticles conjugated with a third antibody directed to a second molecule on the EV, wherein the first molecule and the second molecule are selected from the group consisting of CD63, CD81, CD9, CD24, CD26, CD10, tumor susceptibility gene 101 (TSG101), heat shock 70 kDa protein 4 (HSP70), Rab-5b, programmed cell death 6-interacting protein (AIP1/Alix), aquaporin 2 (AQP2), vascular endothelial growth factor receptor 1 (FLT1), N-glycan containing a fucose residue, phosphocholine, phosphatidylserine, and sphingomyelin; and

detecting whether said cancer specific protein is present in the sample by detecting binding between the second antibody and the cancer specific protein on the EV, wherein dual binding of the two antibody-conjugated nanoparticles to the EV produces nanoplasmons and said nanoplasmons are detected,

wherein the cancer specific protein is ephrin type-A receptor 2 (EphA2), and wherein the EphA2 is associated with pancreatic cancer.

2. The method of claim 1 , wherein the nanoparticles comprise a plurality of nanospheres, a plurality of nanorods, or a combination thereof.

3. The method of claim 2 , wherein the detecting step comprises detecting binding between the second antibody and the EV and detecting binding between the third antibody and the EV.

4. The method of claim 2 , wherein the nanoparticles comprise gold.

5. The method of claim 2 , wherein the first antibody is different from the third antibody.

6. The method of claim 2 , wherein the first antibody is the same as the third antibody.

7. The method of claim 2 , wherein the second antibody is different from the third antibody.

8. The method of claim 2 , wherein the first nanoparticle is different from the second nanoparticle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2021
From: HU, YE; LIANG, KAI; LIU, FEI; FAN, JIA; SUN, DALI
To: THE METHODIST HOSPITAL DBA HOUSTON METHODIST
Reel/Frame 055565/0055 →
Continuity (2)
Provisional Application 62440494 · Dec 30, 2016
Related Publication 20200096516A1 · Mar 26, 2020
References Cited (75)
US 20160003835A1 · Halbert · 2016 [cited by examiner]
US 20190234952A1 · Hu · 2019 [cited by applicant]
WO 2015084800A1 · 2015 [cited by applicant]
WO 2017053516A1 · 2017 [cited by applicant]
Q. Chang et al. Effects of dasatinib on EphA2 receptor tyrosine Kinase act downstream signalling in pancreatic cancer, British J of Cancer, 99, 1074-1082. (Year: 2006). [cited by examiner]
Greg J Nusz et al. Label-Gree Plasmonic Detection of Biuomolecular Binding by a single Gold Nanorod, Anal Chem. 80, 984-989. ( Year: 2008). [cited by examiner]
Yusuke Yoshioka et al., Comparative marker analysis of extracellular vesicles in different human cancer types, Journal of Extracellular Vesicles, 2:1, 20424 (Year: 2013). [cited by examiner]
Greg J Nusz et al., Label-Free Plasmonic Detection of Biomolecular Binding by a single Gold Nanorod, Anal Chem. 80,984-989. (Year: 2008). [cited by examiner]
Kai Liang et al., Nature Biomedical Engineering, 1, Article No. 0021. (Year: 2017). [cited by examiner]
Raposo G, et al. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013; 200:373-383. [PubMed: 23420871]. [cited by applicant]
Rodriguez-Lorenzo L, et al. Plasmonic nanosensors with inverse sensitivity by means of enzyme-guided crystal growth. Nat Mater. 2012; 11:604-607. [PubMed: 22635043]. [cited by applicant]
Shao H, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015; 6:6999. [PubMed: 25959588]. [cited by applicant]
Shao H, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012; 18:1835-1840. [PubMed: 23142818]. [cited by applicant]
Shi L, et al. Plasmon resonance scattering spectroscopy at the single-nanoparticle level: real-time monitoring of a click reaction. Angew Chem Int Ed Engl. 2013; 52:6011-6014. [PubMed: 23616358]. [cited by applicant]
Tanaka Y, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2013; 119:1159-1167. [PubMed: 23224754]. [cited by applicant]
Thery C, et al. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2:569-579. DOI: 10.1038/hri855 [PubMed: 12154376]. [cited by applicant]
Théry C, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006:3.22.21-23.22.29. [PubMed: 18228482]. [cited by applicant]
Vaidyanathan R, et al. Detecting exosomes specifically: a multiplexed device based on alternating current electrohydrodynamic induced nanoshearing. Anal Chem. 2014; 86:11125-11132. [PubMed: 25324037]. [cited by applicant]
Van Der Pol E, et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012; 64:676-705. [PubMed: 22722893]. [cited by applicant]
Yokoi K, et al. Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Cancer Lett. 2013; 334:319-327. [PubMed: 23000514]. [cited by applicant]
Yoshioka Y, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014; 5:3591. [PubMed: 24710016]. [cited by applicant]
Yoshioka, Y, et al. “Comparative marker analysis of extracellular vesicles in different human cancer types.” Journal of extracellular vesicles 2.1 (2013): 20424. [cited by applicant]
Chang, Q., et al., “Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer, ” British Journal of Cancer, vol. 99, published online Sep. 16, 2018, pp. 1074-1082. [cited by applicant]
International Search Report and Written Opinion issued for International Application No. PCT/US2017/068768, mail date Mar. 5, 2018, 11 pages. [cited by applicant]
Anderson HC, et al. Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab Invest. 2010; 90:1549-1557. [PubMed: 20805791]. [cited by applicant]
Anker JN, et al. Biosensing with plasmonic nanosensors. Nat Mater. 2008; 7:442-453. [PubMed: 18497851]. [cited by applicant]
Ansuini H, et al. Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer. J Oncol. 2009; 2009:951917. [PubMed: 20130824]. [cited by applicant]
Archin NM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012:487. [cited by applicant]
Ballehaninna UK, et al. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 2013; 34:3279-3292. [PubMed: 23949878]. [cited by applicant]
Ballehaninna UK, et al. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012; 3:105-119. [PubMed: 2281187… [cited by applicant]
Boukouris S, et al. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015; 9:358-367. [PubMed: 25684126]. [cited by applicant]
Brantley DM, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 2002; 21:7011-7026. [PubMed: 12370823]. [cited by applicant]
Brinton LT, et al. Formation and role of exosomes in cancer. Cell Mol Life Sci. 2015; 72:659-671. [PubMed: 25336151]. [cited by applicant]
Choi Y, et al. Selective and sensitive detection of metal ions by plasmonic resonance energy transfer-based hanospectroscopy. Nat Nanotechnol. 2009; 4:742-746. [PubMed: 19893511]. [cited by applicant]
De Candia P, et al. Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation. PLoS One. 2013; 8:e75348. [PubMed: 24205408]. [cited by applicant]
Del Villano BC, et al. Radioimmunometric assay for monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983; 29:549-552. [PubMed: 6825270]. [cited by applicant]
Dobrzanski P, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Caner Research. 2004; 64:910-919. [cited by applicant]
Duxbury MS, et al. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004; 23:1448-1456. [PubMed: 14973554]. [cited by applicant]
Duxbury MS, et al. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun. 2004; 320:1096-1102. [PubMed: 15249202]. [cited by applicant]
Evans DB, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127:1335-1339. [PubMed: 1359851]. [cited by applicant]
Freelove R, et al. Pancreatic Cancer: Diagnosis and Management. Am Fam Physician. 2006; 73:485-492. [PubMed: 16477897]. [cited by applicant]
Ghosh SK, et al. Interparticle coupling effect on the surface plasmon resonance of gold nanoparticles: from theory to applications. Chem Rev. 2007; 107:4797-4862. [PubMed: 17999554]. [cited by applicant]
Good DM, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res. 2007; 6:4549-4555. [PubMed: 17970587]. [cited by applicant]
Gyorgy B, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011; 68:2667-2688. [PubMed: 21560073]. [cited by applicant]
He M, et al. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip. 2014; 14:3773-3780. [PubMed: 25099143]. [cited by applicant]
Hidalgo M. Pancreatic cancer. N Engl J Med. 2010:362. [cited by applicant]
Hori SS, et al. Mathematical model identifies blood biomarker-based early cancer detection strategies and imitations. Sci Transl Med. 2011; 3:1-9. [cited by applicant]
Im H, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014; 32:490-495. [PubMed: 24752081]. [cited by applicant]
Jazieh KA, et al. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma. Semin Radiat Oncol. 2014; 24:67-76. [PubMed: 24635863]. [cited by applicant]
Jensen MM, et al. Tumor vol. in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008; 8:16. [PubMed: 18925932… [cited by applicant]
Joshi GK, et al. Label-free nanoplasmonic-based short noncoding RNA sensing at attomolar concentrations allows for quantitative and highly specific assay of microRNA-10b in biological fluids and circulating exosomes. AC… [cited by applicant]
Kalra H, et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics. 2013; 13:3354-3364. [PubMed: 24115447]. [cited by applicant]
Kanwar SS, et al. Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip. 2014; 14:1891-1900. [PubMed: 24722878]. [cited by applicant]
Khan S, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7:e46737. [PubMed: 23091600]. [cited by applicant]
Kinch, MS et al. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis. 2003; 20:59-68. [PubMed: 12650608]. [cited by applicant]
Kowal J, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci. 2016; 113:E968-977. [PubMed: 26858453]. [cited by applicant]
Lane RE, et al. Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing. Sci Rep. 2015; 5:7639. [PubMed: 25559219]. [cited by applicant]
Lee K, et al. Quantitative imaging of single mRNA splice variants in living cells. Nat Nanotechnol. 2014; 9:474-480. [PubMed: 24747838]. [cited by applicant]
Lescuyer P, et al. How shall we use the proteomics toolbox for biomarker discovery? J Proteome Res. 2007; 6:3371-3376. [PubMed: 17655344]. [cited by applicant]
Li D, et al. Pancreatic cancer. The Lancet. 2004; 363:1049-1057. [cited by applicant]
Link S, et al. Spectral properties and relaxation dynamics of surface plasmon electronic oscillations in gold and silver hanodots and nanorods. J Phys Chem B. 1999; 103:8410-8426. [cited by applicant]
Locker GY, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24:5313-5327. [PubMed: 17060676]. [cited by applicant]
Logozzi M, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009; 4:e5219. [PubMed: 19381331]. [cited by applicant]
Logsdon CD, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003; 63:2649-2657. [PubMed: 12750293]. [cited by applicant]
Lowenfels AB, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993; 328:1433-1437. [PubMed: 8479461]. [cited by applicant]
Melo SA, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015; 523:177-182. [PubMed: 26106858]. [cited by applicant]
Miyazaki T, et al. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer. 2003; 103:657-663. [PubMed: 12494475]. [cited by applicant]
Mudali SV, et al. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis. 2006; 23:357-365. [PubMed: 17146615]. [cited by applicant]
Muralidharan-Chari V, et al. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010; 123:1603-1611. [PubMed: 20445011]. [cited by applicant]
Nusz GJ, et al. Label-free plasmonic detection of biomolecular binding by a single gold nanorod. Anal Chem. 2008; 80:984-989. [PubMed: 18197636]. [cited by applicant]
O'Driscoll L. Expanding on exosomes and ectosomes in cancer. N Engl J Med. 2015:372. [cited by applicant]
Pei H, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009; 16:259-266. [PubMed: 19732725]. [cited by applicant]
Peinado H, et al. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med. 2012; 18:883-891. [PubMed: 22635005]. [cited by applicant]
Rabinowits G, et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009; 10:42-46. [PubMed: 19289371]. [cited by applicant]
Oldenburg et al., “Topics in Fluorescence Spectroscopy vol. 8 Radiative Decay Engineering”, Geddes, Springer, 333-346, 2005. [cited by applicant]